Immatics Announces Business Combination with Arya Sciences Acquisition Corp., Creating a Publicly Listed Leader in TCR-based Immunotherapies
- Upon successful completion of the business combination, Immatics will receive up to approximately $148 million of cash held within Arya’s trust account
- Leading institutional investors commit $104 million of cash through a common stock private investment in public equity (“PIPE”) led by Perceptive Advisors and other top-tier US healthcare investors
- Immatics shareholders, Arya shareholders and PIPE investors will hold sharesin the newly formed company with the name Immatics N.V. that is expected to be listed on NASDAQ under the ticker symbol “IMTX”
- Business combination completion is expected in the second quarter of 2020
- Joint investor conference call to discuss the proposed transaction today, Tuesday, March 17, 2020 at 10:30 am ET
Immatics Biotechnologies GmbH (“Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced it has entered into a definitive business combination agreement with Arya Sciences Acquisition Corp. (NASDAQ: ARYA) (“Arya”), a special purpose acquisition company,sponsored by Perceptive Advisors.